hepatitis C

Intravenous drug users are in a high-risk category for hepatitis C.

静脉注射毒品的是患型炎的高危。

In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.

在感染者中，重叠感染隐匿HBV会影响干扰素的疗效。

Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.

研究结果显示，慢，TH1活素表达显著并与免疫理机制相关。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿是慢型炎（CHC）中纤维化进展以及对抗毒治疗无应答的危险因素。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢（CHC）患者接受α干扰素包括派罗欣治疗时存在功能失代偿和死亡风险。